Thomas Chung's Biography

Thomas Chung, Director of Outreach/Project Manager, Sanford Burnham Medical Research Institute

Dr. Chung is the Project Manager at the Sanford-Burnham Medical Research Institute's screening center. Since September 2007, Dr. Chung has been responsible for strategic and tactical operations for HTS and chemical genomics, with over 20 years in drug discovery in roles of increasing responsibility from bench R&D to Executive for major several pharmaceutical companies and (DuPont Pharmaceutical, BMS, Merck, and GSK) and start-ups (Pharmacopeia and Genoptix), to Chief Scientific Officer. He has built and led world-class R&D teams and facilities that developed, acquired and integrated novel technologies in imaging, signal generation and detection, liquid handling, miniaturization, IT, high-throughput screening, biochemical and cell-based assay development, laboratory automation and robotics, compound management, Lead optimization, ADME/Tox profiling and analytical chemistry (HPLC/MS). Dr. Chung has managed discovery programs in cardiovascular, CNS, infectious, inflammatory and cancer diseases, with expertise in biochemistry, molecular and cellular biology, over 35 papers and book chapters, 10 issued and pending patents.

Seeding Open Innovation in Drug Discovery and Translational Research through Collaboration Models Leveraging Government Funding: Mayo Clinic and Florida Translational Research Programs

Tuesday, 17 September 2013 at 12:00

Add to Calendar ▼2013-09-17 12:00:002013-09-17 13:00:00Europe/LondonSeeding Open Innovation in Drug Discovery and Translational Research through Collaboration Models Leveraging Government Funding: Mayo Clinic and Florida Translational Research ProgramsAcademic Screening Workshop 2013 in Baltimore, MA, USABaltimore, MA, USASELECTBIOenquiries@selectbiosciences.com

With costs (>$1B per NCE) and duration (10-15Y) of traditional R&D as practiced, "big Pharma" has come under increased scrutiny and assault from disease advocacy groups, government and investment communities as being too high and long, stagnant, and unsustainable. They have raised a clarion call for new innovative business models for drug discovery and development, in particular the participation the best of academia to catalyze new innovation and translational research. Leveraging our Prebys Center's experience in “open innovation” as a Comprehensive Screening Center of the NIH's Molecular Libraries Probe Production Centers Network (MLPCN), we established new models of academic drug discovery and development that leverage alternative sources of government and public funding with clinical translational partners. In this talk, we provide a case study of the motivations and working operational models and our strategic alliance and partnership with the Mayo Clinic and a more recent alliance with the State of Florida.

Add to Calendar ▼2013-09-17 00:00:002013-09-18 00:00:00Europe/LondonAcademic Screening Workshop 2013Academic Screening Workshop 2013 in Baltimore, MA, USABaltimore, MA, USASELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors